Overview

ZD6474 Phase IIa Dose Finding Multicentre Study

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Criteria
Inclusion Criteria:

- Provision of written informed consent.

- Life expectancy of 12 weeks or longer.

Exclusion Criteria:

- Pregnancy, breast feeding or female patients wishing to become pregnant.

- Treatment with a non-approved or investigational drug within 30 days before enrolment